Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape.
Martin CJ, Datta A, Littlefield C, Kalra A, Chapron C, Wawersik S, Dagbay KB, Brueckner CT, Nikiforov A, Danehy FT Jr, Streich FC Jr, Boston C, Simpson A, Jackson JW, Lin S, Danek N, Faucette RR, Raman P, Capili AD, Buckler A, Carven GJ, Schürpf T.
Martin CJ, et al. Among authors: wawersik s.
Sci Transl Med. 2020 Mar 25;12(536):eaay8456. doi: 10.1126/scitranslmed.aay8456.
Sci Transl Med. 2020.
PMID: 32213632